DOCS Stock Overview
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$67.65|
|52 Week High||US$107.79|
|52 Week Low||US$41.17|
|1 Month Change||-2.63%|
|3 Month Change||-25.66%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||27.64%|
Recent News & Updates
Doximity: Better Than Teladoc, But Still Not Worth Buying
As the world continues to recover from the Covid-19 pandemic, the stocks that saw pandemic tailwinds are now fading. Doximity is a digital health network that is making strides in telemedicine. However, it appears the tide is now going out on this sort of company. Meanwhile, shares are still trading for more than 40x revenues. Doximity seems like a better investment than the more well-known Teladoc. Still, both look like bad picks for the time being.
Shareholders Can Be Confident That Doximity's (NYSE:DOCS) Earnings Are High Quality
Even though Doximity, Inc.'s ( NYSE:DOCS ) recent earnings release was robust, the market didn't seem to notice...
|DOCS||US Healthcare Services||US Market|
Return vs Industry: Insufficient data to determine how DOCS performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how DOCS performed against the US Market.
|DOCS Average Weekly Movement||11.2%|
|Healthcare Services Industry Average Movement||8.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.0%|
|10% least volatile stocks in US Market||2.3%|
Stable Share Price: DOCS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: Insufficient data to determine DOCS's volatility change over the past year.
About the Company
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company’s cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems.
Doximity Fundamentals Summary
|DOCS fundamental statistics|
Is DOCS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DOCS income statement (TTM)|
|Cost of Revenue||US$32.80m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.34|
|Net Profit Margin||22.81%|
How did DOCS perform over the long term?See historical performance and comparison
Is Doximity undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DOCS ($67.65) is trading above our estimate of fair value ($25.01)
Significantly Below Fair Value: DOCS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DOCS is poor value based on its PE Ratio (200.5x) compared to the US Healthcare Services industry average (102.2x).
PE vs Market: DOCS is poor value based on its PE Ratio (200.5x) compared to the US market (16.8x).
Price to Earnings Growth Ratio
PEG Ratio: DOCS is poor value based on its PEG Ratio (26.9x)
Price to Book Ratio
PB vs Industry: DOCS is overvalued based on its PB Ratio (16.4x) compared to the US Healthcare Services industry average (4.3x).
How is Doximity forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DOCS's forecast earnings growth (7.5% per year) is above the savings rate (2%).
Earnings vs Market: DOCS's earnings (7.5% per year) are forecast to grow slower than the US market (14.2% per year).
High Growth Earnings: DOCS's earnings are forecast to grow, but not significantly.
Revenue vs Market: DOCS's revenue (23.4% per year) is forecast to grow faster than the US market (10.1% per year).
High Growth Revenue: DOCS's revenue (23.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DOCS's Return on Equity is forecast to be low in 3 years time (15.1%).
How has Doximity performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: DOCS has high quality earnings.
Growing Profit Margin: DOCS's current net profit margins (22.8%) are higher than last year (9.7%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DOCS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare DOCS's past year earnings growth to its 5-year average.
Earnings vs Industry: DOCS earnings growth over the past year (318.2%) exceeded the Healthcare Services industry 17%.
Return on Equity
High ROE: DOCS's Return on Equity (13.1%) is considered low.
How is Doximity's financial position?
Financial Position Analysis
Short Term Liabilities: DOCS's short term assets ($829.6M) exceed its short term liabilities ($95.6M).
Long Term Liabilities: DOCS's short term assets ($829.6M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: DOCS is debt free.
Reducing Debt: DOCS has not had any debt for past 5 years.
Debt Coverage: DOCS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: DOCS has no debt, therefore coverage of interest payments is not a concern.
What is Doximity current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DOCS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DOCS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DOCS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DOCS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DOCS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Tangney (48 yo)
Mr. Jeffrey A. Tangney, also known as Jeff, Co-Founded Doximity, Inc. in 2010 and serves as its Chief Executive Officer and Director since April 2010. Mr. Tangney also serves as an Advisor at Rock Health....
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD21.31M) is above average for companies of similar size in the US market ($USD11.14M).
Compensation vs Earnings: Insufficient data to compare Jeff's compensation with company performance.
Experienced Management: DOCS's management team is seasoned and experienced (6.5 years average tenure).
Experienced Board: DOCS's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: DOCS only recently listed within the past 12 months.
Doximity, Inc.'s employee growth, exchange listings and data sources
- Name: Doximity, Inc.
- Ticker: DOCS
- Exchange: NYSE
- Founded: 2010
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$12.685b
- Shares outstanding: 187.51m
- Website: https://www.doximity.com
Number of Employees
- Doximity, Inc.
- 500, 3rd Street
- Suite 510
- San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/01 00:09|
|End of Day Share Price||2021/11/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.